Biologics Market Report, Size, Trends, Emerging Growth Factors, Forecast 2024-2032

Written by Mark Smith  »  Updated on: September 12th, 2024

The latest report by IMARC Group, titled “Biologics Market: Global Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2032,” offers a comprehensive analysis of the biologics market size. The report also includes competitor and regional analysis, along with a breakdown of segments within the industry.

The global biologics market size reached US$ 349.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 699.5 Billion by 2032, exhibiting a growth rate (CAGR) of 7.8% during 2024-2032.

Biologics are complex medications derived from living organisms, used to treat and prevent various diseases by precisely targeting specific cellular pathways. Unlike traditional pharmaceuticals synthesized chemically, biologics are produced using biotechnology methods involving recombinant DNA technology, gene modification, and cultured cells. They include a range of products such as monoclonal antibodies, vaccines, recombinant proteins, and cell therapies. Each type of biologic serves a distinct purpose; monoclonal antibodies, for example, are used for cancer and autoimmune diseases, while vaccines are crucial for preventing infections. The advantages of biologics include their ability to treat previously untreatable conditions, reduced side effects compared to conventional drugs, and higher specificity in targeting disease mechanisms. Their development is revolutionizing treatment paradigms across oncology, immunology, and endocrinology, offering new hope to patients with complex health issues.

Get a Sample Copy of this Report: https://www.imarcgroup.com/biologics-market/requestsample

Market Trends:

The global biologics market is experiencing significant growth, fueled by advancements in biomedical research and an aging global population with complex health needs. Along with this, the market's expansion is largely driven by the increasing prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders, where biologics have proven effective in managing symptoms and improving patient outcomes. Technological innovations in genetic engineering and cell culture have also accelerated the development and production of new biologic therapies, enhancing their efficacy and safety profiles.

Furthermore, regulatory support for faster approval of biologic drugs, particularly in the U.S. and EU, has expedited their introduction to the market. In addition, the growing acceptance and demand for personalized medicine, which often relies on biologics due to their tailored treatment capabilities, continue to drive market expansion. Furthermore, significant investments in biotech R&D, coupled with strategic collaborations between pharmaceutical giants and biotech startups, are nurturing the pipeline of biologics and ensuring a steady flow of innovative treatments. These factors collectively contribute to the robust growth trajectory of the global biologics market, promising transformative impacts on healthcare and patient care standards worldwide.

View Full Report with TOC & List of Figure: https://www.imarcgroup.com/biologics-market

Competitive Landscape:

The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Sanofi

Biologics Market Segmentation:

Our report has categorized the market based on region, source, product, disease and manufacturing.

Breakup by Source:

  • Microbial
  • Mammalian
  • Others

Breakup by Product:

  • Monoclonal Antibodies
  • Vaccines
  • Recombinant Proteins
  • Antisense, RNAi and Molecular Therapy
  • Others

Breakup by Disease:

  • Oncology
  • Immunological Disorders
  • Cardiovascular Disorders
  • Hematological Disorders
  • Others

 Breakup by Manufacturing:

  • Outsourced
  • In-House

Breakup by Region:

  • North America (United States, Canada)
  • Europe (Germany, France, United Kingdom, Italy, Spain, Others)
  • Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
  • Latin America (Brazil, Mexico, Others)
  • Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)

Key highlights of the report:

  • Market Performance (2018-2023)
  • Market Outlook (2024-2032)
  • Porter’s Five Forces Analysis
  • Market Drivers and Success Factors
  • SWOT Analysis
  • Value Chain
  • Comprehensive Mapping of the Competitive Landscape

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US:

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: [email protected]
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145


Disclaimer:

We do not claim ownership of any content, links or images featured on this post unless explicitly stated. If you believe any content infringes on your copyright, please contact us immediately for removal ([email protected]). Please note that content published under our account may be sponsored or contributed by guest authors. We assume no responsibility for the accuracy or originality of such content.


Related Posts